Article
Oncology
Kartik Iyer, Shangsi Ren, Lucy Pu, Summer Mazur, Xiaoyan Zhao, Rajeev Dhupar, Jiantao Pu
Summary: This study aimed to model the causal relationship between radiographical features derived from CT scans and postoperative lung cancer recurrence and recurrence-free survival. Body composition, particularly with respect to adipose tissue distribution, was found to have a significant and causal impact on both recurrence and recurrence-free survival. The accurate identification of the preoperative factors impacting postoperative cancer recurrence is crucial for optimizing neoadjuvant and adjuvant therapies and guiding follow-up treatment plans.
Article
Immunology
Jia-Chun Ma, Jing-Xin Zhang, Fei Wang, Jinming Yu, Dawei Chen
Summary: This study demonstrates the survival benefits of immunotherapy in patients with oligometastatic NSCLC, with particular benefit observed in patients with brain or multiple organ metastases.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Kazuhito Ueki, Yukinori Matsuo, Atsuya Takeda, Satoshi Morita, Masataka Taguri, Noriko Kishi, Hideki Hanazawa, Yuichiro Tsurugai, Takashi Mizowaki
Summary: The study aimed to assess the impact of local recurrence (LR) on cause-specific death (CSD) in non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT). A dynamic prediction model incorporating LR as a time-dependent covariate was used. The findings showed that LR significantly influenced subsequent CSD, supporting strategies to improve local control.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Review
Oncology
Heidi Rutten, Cornelia Verhoef, Willem Jan van Weelden, Anke Smits, Joelle Dhanis, Nelleke Ottevanger, Johanna M. A. Pijnenborg
Summary: The treatment strategies for recurrent endometrial cancer should be personalized based on the individual patient and tumor characteristics. Local and locoregional recurrences can be curatively treated with surgery or radiotherapy, while distant recurrences may require palliative systemic therapy. Further studies are needed to assess the effectiveness and toxicity of newer treatment strategies in this challenging condition.
Review
Oncology
Yi-Hsing Chen, Ue-Cheung Ho, Lu-Ting Kuo
Summary: Oligometastatic non-small-cell lung cancer (NSCLC) is a distinct group of patients that could benefit from curative-intent treatment to improve clinical outcomes. Various treatment procedures have been developed for different oligometastatic sites. The proposed uniform definition for oligometastases and ongoing trials may enhance patient selection and evaluation of treatment effectiveness.
Article
Genetics & Heredity
Brandilyn A. Peters, Harvey Pass, Robert D. Burk, Xiaonan Xue, Chandra Goparaju, Christopher C. Sollecito, Evan Grassi, Leopoldo N. Segal, Jun-Chieh J. Tsay, Richard B. Hayes, Jiyoung Ahn
Summary: In this study, the lung microbiome and peripheral blood gene expression were investigated as potential biomarkers for predicting lung cancer recurrence after tumor resection. The results showed that certain microbial and gene profiles were associated with recurrence-free survival and disease-free survival, providing additional predictive value beyond standard demographic and clinical factors.
Article
Oncology
Cecile Le Pechoux, Nicolas Pourel, Fabrice Barlesi, Delphine Lerouge, Delphine Antoni, Bruno Lamezec, Ursula Nestle, Pierre Boisselier, Eric Dansin, Amaury Paumier, Karine Peignaux, Francois Thillays, Gerard Zalcman, Jeannick Madelaine, Eric Pichon, Anne Larrouy, Armelle Lavole, Delphine Argo-Leignel, Marc Derollez, Corinne Faivre-Finn, Matthew Q. Hatton, Oliver Riesterer, Emilie Bouvier-Morel, Ariane Dunant, John G. Edwards, Pascal Alexandre Thomas, Olaf Mercier, Aurelie Bardet
Summary: This study aimed to investigate whether three-dimensional conformal radiotherapy (3D PORT) should be part of the standard treatment for patients with non-small-cell lung cancer (NSCLC) with N2 involvement. The results showed that 3-year disease-free survival was slightly higher in patients with PORT compared to those without, but the difference was not significant.
Article
Oncology
Shao-Hua Li, Jie Mei, Yuan Cheng, Qiang Li, Qiao-Xuan Wang, Chong-Kai Fang, Qiu-Cheng Lei, Hua-Kun Huang, Ming-Rong Cao, Rui Luo, Jing-Duo Deng, Yu-Chuan Jiang, Rong-Ce Zhao, Liang-He Lu, Jing-Wen Zou, Min Deng, Wen-Ping Lin, Ren-Guo Guan, Yu-Hua Wen, Ji-Bin Li, Lie Zheng, Zhi-Xing Guo, Yi-Hong Ling, Huan-Wei Chen, Chong Zhong, Wei Wei, Rong-Ping Guo
Summary: This study investigated the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and oxaliplatin (FOLFOX) in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI). The results showed that HAIC significantly improved disease-free survival (DFS) and had acceptable toxicities compared to routine follow-up.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yilin Cao, Hanbo Chen, Arjun Sahgal, Darby Erler, Serena Badellino, Tithi Biswas, Roi Dagan, Matthew C. Foote, Alexander V. Louie, Ian Poon, Umberto Ricardi, Kristin J. Redmond
Summary: This study investigated the impact of local control (LC) on widespread progression (WSP) and overall survival (OS) in patients treated to all extracranial oligometastases (OMs) at presentation to SBRT. The study found that patients who failed locally within 6 months after SBRT were at a significantly higher risk of death and WSP compared to those who remained locally-controlled. The duration of LC following OM-directed SBRT strongly correlated with WSP and OS. Rating: 6 out of 10.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Xin-ru Chen, Xue Hou, De-lan Li, Ke Sai, Xiao-xiao Dinglin, Jing Chen, Na Wang, Mei-chen Li, Kai-cheng Wang, Li-kun Chen
Summary: The optimal initial treatment strategy for non-small-cell lung cancer patients initially diagnosed with 1 to 3 synchronous brain metastases is still unknown. However, local therapy to both lung and brain lesions may lead to longer overall survival, highlighting the importance of comprehensive treatment in these patients.
CLINICAL LUNG CANCER
(2021)
Article
Oncology
Hisao Imai, Ryoichi Onozato, Kyoichi Kaira, Sayaka Kawashima, Ken Masubuchi, Toshiteru Nagashima, Kohei Tajima, Koichi Minato
Summary: The post-progression survival (PPS) is significantly more strongly associated with overall survival (OS) than relapse-free survival (RFS) in patients with postoperative recurrence of NSCLC. This suggests that treatment following postoperative recurrence plays a crucial role in patient survival outcomes and should be further investigated in large prospective studies.
Article
Multidisciplinary Sciences
Toshiki Ikawa, Takahiro Tabuchi, Koji Konishi, Masahiro Morimoto, Takero Hirata, Naoyuki Kanayama, Kentaro Wada, Masayasu Toratani, Sumiyo Okawa, Kazuhiko Ogawa, Teruki Teshima
Summary: In a retrospective study of 200 patients with early-stage non-small-cell lung cancer, consecutive stereotactic body radiotherapy was found to provide better local control and overall survival compared to non-consecutive treatment. The prolonged overall treatment time negatively impacted outcomes in patients undergoing stereotactic body radiotherapy.
Article
Oncology
Tomoyoshi Takenaka, Tokujiro Yano, Koji Yamazaki, Tatsuro Okamoto, Motoharu Hamatake, Shinkichi Takamori, Mikihiro Kohno, Naoko Miura, Mototsugu Shimokawa, Tomoharu Yoshizumi, Kyushu Univ Lung Surg Study Grp
Summary: This study evaluated the post-recurrence survival after treatment of postoperative recurrent EGFR mutated NSCLC and examined the effectiveness of radical local therapy. The results showed that although radical local therapy may be curative in some patients, chemotherapy including EGFR-TKI treatment is expected to provide long-term survival rates comparable to radical local therapy.
Review
Oncology
Jamie E. Chaft, Yu Shyr, Boris Sepesi, Patrick M. Forde
Summary: Biomarker-informed clinical trials are pushing the treatment of early-stage lung cancer beyond cytotoxic chemotherapy, with the incorporation of targeted and immunotherapies. Adjuvant osimertinib, preoperative chemoimmunotherapy, and adjuvant immunotherapy could improve outcomes for resectable lung cancer patients, and ongoing or planned studies focusing on biomarkers, immunotherapy, and targeted therapy may further enhance survival.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Mahdi Sheikh, Anush Mukeriya, Oxana Shangina, Paul Brennan, David Zaridze
Summary: Smoking cessation after diagnosis of early-stage lung cancer was associated with significantly improved overall survival, progression-free survival, and decreased risks for all-cause mortality, cancer-specific mortality, and disease progression among current smokers. Effects were consistent across different smoking levels and cancer stages.
ANNALS OF INTERNAL MEDICINE
(2021)